Invest in Artificial Intelligence Before It Changes the World
A.I. is going to be one of the dominant themes over the next decade, as companies automate their businesses and use A.I. to remain competitive. This is the golden age of investing in artificial intelligence!
Invest in this red-hot industry at pre-IPO prices.
Susan Molineaux, insider at Calithera Biosciences

Susan Molineaux Insider Information

Dr. Molineaux is the co-founder, President and CEO of Calithera Biosciences, a start-up company that commenced operations in June of 2010. Prior to starting Calithera, Dr. Molineaux was a co-founder of Proteolix and served as the CSO for two years before becoming President and CEO of the company. Proteolix was acquired by Onyx Pharmaceuticals in November 2009. Prior to joining Proteolix, Dr. Molineaux was Vice President of Biology at Rigel Pharmaceuticals from 2000 to 2003. Before that, she was Vice President of Biology at Praelux, and from 1994 through 1999, Dr. Molineaux served as Vice President of Drug Development at Praecis Pharmaceuticals. From 1989 until 1994 she was a scientist in the immunology group at Merck, in Rahway, NJ.

Education:
B.S. in Biology from Smith College
Ph.D. in Molecular Biology from Johns Hopkins University
Postdoctoral fellowship at Columbia University

How old is Susan Molineaux?

Dr. Molineaux is currently 68 years old. There are 4 older executives and no younger executives at Calithera Biosciences. Learn More on Susan Molineaux's age.

What is Susan Molineaux's salary?

As the CEO of Calithera Biosciences, Inc., Dr. Molineaux earned a total compensation package of $3,620,571.00 in 2020. Dr. Molineaux earned a salary of $569,250.00, a bonus of $222,008.00, options awards of $2,813,619.00, and other compensation of $15,694.00. Learn More on Susan Molineaux's salary.

How do I contact Susan Molineaux?

The corporate mailing address for Dr. Molineaux and other Calithera Biosciences executives is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. Calithera Biosciences can also be reached via phone at (650) 870-1000 and via email at [email protected] Learn More on Susan Molineaux's contact information.

Has Susan Molineaux been buying or selling shares of Calithera Biosciences?

Susan Molineaux has not been actively trading shares of Calithera Biosciences over the course of the past ninety days. Most recently, 0 shares of the firm's stock in a transaction dated Wednesday, May 18th. Learn More on Susan Molineaux's trading history.

Who are Calithera Biosciences' active insiders?

Calithera Biosciences' insider roster includes Susan Molineaux (CEO), and Keith Orford (Director). Learn More on Calithera Biosciences' active insiders.

Are insiders buying or selling shares of Calithera Biosciences?

During the last twelve months, Calithera Biosciences insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $85,000.00. During the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 100,000 shares worth more than $85,927.60. The most recent insider tranaction occured on November, 11th when Director Keith Orford sold 48,190 shares worth more than $42,407.20. Insiders at Calithera Biosciences own 11.6 % of the company. Learn More about insider trades at Calithera Biosciences.

Information on this page was last updated on 11/11/2021.

Susan Molineaux Insider Trading History at Calithera Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/10/2021Buy100,000$0.85$85,000.00View SEC Filing Icon  
6/25/2019Buy51,600$3.88$200,208.00View SEC Filing Icon  
See Full Table

Susan Molineaux Buying and Selling Activity at Calithera Biosciences

This chart shows Susan Molineaux's buying and selling at Calithera Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Calithera Biosciences Company Overview

Calithera Biosciences logo
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.19
Low: $0.19
High: $0.22

50 Day Range

MA: $0.35
Low: $0.16
High: $0.63

2 Week Range

Now: $0.19
Low: $0.15
High: $2.59

Volume

1,538,784 shs

Average Volume

2,741,651 shs

Market Capitalization

$15.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64
This is the golden age of investing in artificial intelligence!
A.I. is going to be one of the dominant themes over the next decade, as companies automate their businesses and use A.I. to remain competitive.
Invest in this red-hot industry at pre-IPO prices.